Background/Aims: Cognitive impairment is frequent in cerebrovascular disease but often remains undetected. The Montreal Cognitive Assessment (MoCA) has been proposed in this context. Our aim was to evaluate the MoCA and its subtests in cerebrovascular disease. Methods: We assessed 386 consecutive patients with minor stroke (National Institutes of Health Stroke Score <4) or transient ischemic attack at 3 months. The MoCA and the modified Rankin Scale (mRS) were administered. Computed tomography (CT) scans were assessed for stroke and white matter changes. An unfavorable functional outcome was defined as mRS >1. Results: The prevalence of cognitive impairment (cutoff of 26) was 55% using the MoCA and 13% using the MMSE. In a multivariate analysis, MoCA <26 was associated with the outcome (OR 3.00, CI 1.78-5.03), as were remote lacunar stroke on CT and white matter changes of at least moderate severity. Five subtests (5-word recall, word list generation, trail-making, abstract reasoning and cube copy) formed an optimal short MoCA with 6/10 or less showing a sensitivity of 91% and a specificity of 83%. Conclusion: This study extends the utility of the MoCA to milder forms of cerebrovascular disease. The MoCA is associated with the 3-month functional outcome. Five subtests may constitute an optimal brief tool in vascular cognitive impairment.

Tatemichi TK, Paik M, Bagiella E, Desmond DW, Pirro M, Hanzawa LK: Dementia after stroke is a predictor of long-term survival. Stroke 1994;25:1915-1919.
Snaphaan L, de Leeuw FE: Poststroke memory function in nondemented patients: a systematic review on frequency and neuroimaging correlates. Stroke 2007;38:198-203.
Lodder J: Poststroke cognition and the fight against the hard problem: vascular neurologists, enter the arena! Stroke 2007;38:7-8.
Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F: Poststroke dementia. Lancet Neurol 2005;4:752-759.
Brodaty H, Altendorf A, Withall A, Sachdev PS: Mortality and institutionalization in early survivors of stroke: the effects of cognition, vascular mild cognitive impairment, and vascular dementia. J Stroke Cerebrovasc Dis 2010;19:485-493.
Pasquini M, Leys D, Rousseaux M, Pasquier F, Henon H: Influence of cognitive impairment on the institutionalisation rate 3 years after a stroke. J Neurol Neurosurg Psychiatry 2007;78:56-59.
Wagle J, Farner L, Flekkoy K, Bruun Wyller T, Sandvik L, et al: Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. Dement Geriatr Cogn Disord 2011;31:379-387.
Pendlebury ST, Cuthbertson FC, Welch SJ, Mehta Z, Rothwell PM: Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 2010;41:1290-1293.
Toglia J, Fitzgerald KA, O'Dell MW, Mastrogiovanni AR, Lin CD. The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. Arch Phys Med Rehabil 2011;92:792-798.
Savitz SI, Benatar M, Saver JL, Fisher M: Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choices. Cerebrovasc Dis 2008;26:156-162.
Kasner SE: Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-612.
Planton M, Peiffer S, Albucher JF, Barbeau EJ, Tardy J, Pastor J, Januel AC, Bezy C, Lemesle B, Puel M, Demonet JF, Chollet F, Pariente J: Neuropsychological outcome after a first symptomatic ischaemic stroke with ‘good recovery'. Eur J Neurol 2012;19:212-219.
Tatemichi TK: How acute brain failure becomes chronic: a view of the mechanisms of dementia related to stroke. Neurology 1990;40:1652-1659.
van Dijk EJ, de Leeuw FE: Recovery after stroke: more than just walking and talking again. If you don't look for it, you won't find it. Eur J Neurol 2012;19:189-190.
Lindsay P, Bayley M, McDonald A, Graham ID, Warner G, Phillips S: Toward a more effective approach to stroke: Canadian Best Practice Recommendations for Stroke Care. CMAJ 2008;178:1418-1425.
Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG: National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220-2241.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
Bocti C, Black S, Frank C: Management of dementia with a cerebrovascular component. Alzheimers Dement 2007;3:398-403.
Bour A, Rasquin S, Boreas A, Limburg M, Verhey F: How predictive is the MMSE for cognitive performance after stroke? J Neurol 2010;257:630-637.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, revised. Washington, 1994.
van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J: Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 1990;53:1080-1083.
Ovbiagele B, Lyden PD, Saver JL, VISTA Collaborators: Disability status at 1 month is a reliable proxy for final ischemic stroke outcome. Neurology 2010;75:688-692.
Kasai M, Meguro K, Nakamura K, Nakatsuka M, Ouchi Y, et al: Screening for very mild subcortical vascular dementia patients aged 75 and above using the Montreal Cognitive Assessment and Mini-Mental State Examination in a community: the Kurihara project. Dement Geriatr Cogn Disord Extra 2012;2:503-515.
Wong A, Xiong YY, Kwan PW, et al: The validity, reliability and clinical utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. Dement Geriatr Cogn Disord 2009;28:81-87.
Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, Lamy C, Canaple S, Petitnicolas G: Is the Montreal Cognitive Assessment superior to the Mini-Mental State Examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke 2011;42:1712-1716.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.